Last updated on February 2018

Study of Iomab-B Prior to HCT vs. Conventional Care in Older Subjects With Active Relapsed or Refractory AML


Brief description of study

The primary objective of this study is to demonstrate the efficacy of Iomab-B, in conjunction with a Reduced Intensity Conditioning (RIC) regimen and protocol-specified allogeneic hematopoietic stem cell transplant (HCT), versus Conventional Care.

Clinical Study Identifier: NCT02665065

Contact Investigators or Research Sites near you

Start Over

Kevin Zikaras

Banner MD Anderson Cancer Center
Gilbert, AZ United States
  Connect »

Kevin Zikaras

Yale Cancer Center
New Haven, CT United States
  Connect »

Kevin Zikaras

Mayo Clinic
Jacksonville, FL United States
  Connect »

Kevin Zikaras

Loyola University Medical Center
Maywood, IL United States
  Connect »

Kevin Zikaras

The University of Kansas Cancer Center
Westwood, KS United States
  Connect »

Kevin Zikaras

Mayo Clinic
Rochester, MN United States
  Connect »

Kevin Zikaras

Washington University School of Medicine
Saint Louis, MO United States
  Connect »

Kevin Zikaras

Roswell Park Cancer Institute
Buffalo, NY United States
  Connect »

Kevin Zikaras

Memorial Sloan Kettering Cancer Center
New York, NY United States
  Connect »

Kevin Zikaras

University Hospitals Cleveland Medical Center
Cleveland, OH United States
  Connect »

Kevin Zikaras

The Ohio State University Comprehensive Cancer Center
Columbus, OH United States
  Connect »

Kevin Zikaras

Penn State Hershey Cancer Institute
Hershey, PA United States
  Connect »

Kevin Zikaras

Baylor Charles A. Sammons Cancer Center
Dallas, TX United States
  Connect »

Kevin Zikaras

MD Anderson Cancer Center
Houston, TX United States
  Connect »

Kevin Zikaras

Fred Hutchinson Cancer Research Center
Seattle, WA United States
  Connect »